

Cilostazol Criteria for Use June 2023

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Exclusion Criteria

If the answer to the item below is met, then the patient should NOT receive cilostazol

Heart failure with reduced ejection fraction¹

1. Note: FDA labeling does not specify the classification or degree of heart failure severity that should be avoided. The concern is based on extrapolated data from oral milrinone where patients with class III and IV heart failure (with reduced ejection fraction) had lower survival.

Prepared: June 2023. Contact: Lisa Longo PharmD, BCPS, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)
